Overview

• Novo Nordisk announced that CEO Lars Fruergaard Jørgensen will step down after leading the company since 2017.
• Under Jørgensen's leadership, Novo Nordisk became a market leader in obesity and diabetes treatments but has recently faced significant competition from Eli Lilly.
• The company’s stock has declined 32% since the start of 2025, including a more than 2% drop on Friday on the Copenhagen Stock Exchange.
• Novo Nordisk reaffirmed its 2025 financial outlook, signaling confidence in its strategic direction despite the leadership change.
• Analyst reactions to the announcement were mixed, with some viewing it as a negative surprise and others praising it as a decisive move to address market pressures.